TY - JOUR
T1 - Annotation mobile pump deep vein thrombosis prophylaxis just say no to drugs
AU - Haynes, J.
AU - Barrack, R. L.
AU - Nam, D.
N1 - Publisher Copyright:
© 2017 The British Editorial Society of Bone & Joint Surgery.
PY - 2017/1
Y1 - 2017/1
N2 - Aims The purpose of this article was to review the current literature pertaining to the use of mobile compression devices (MCDs) for venous thromboembolism (VTE) following total joint arthroplasty (TJA), and to discuss the results of data from our institution. Patients and Methods Previous studies have illustrated higher rates of post-operative wound complications, reoperation and re-admission with the use of more aggressive anticoagulation regimens, such as warfarin and factor Xa inhibitors. This highlights the importance of the safety, as well as efficacy, of the chemoprophylactic regimen. Results Studies have shown a symptomatic VTE rate of 0.92% with use of MCDs for prophylaxis, which is comparable with rates seen with more aggressive anticoagulation protocols. A prior prospective study found that use of a pre-operative risk stratification protocol based on personal history of deep vein thrombosis, family history of VTE, active cancer, or a hypercoaguable state allowed for the avoidance of aggressive prophylactic anticoagulation in over 70% of patients while maintaining a low incidence of symptomatic VTE. Conclusion Further investigation is needed into the role of aspirin in VTE prophylaxis as well as the efficacy of MCDs as stand-alone prophylactic treatment.
AB - Aims The purpose of this article was to review the current literature pertaining to the use of mobile compression devices (MCDs) for venous thromboembolism (VTE) following total joint arthroplasty (TJA), and to discuss the results of data from our institution. Patients and Methods Previous studies have illustrated higher rates of post-operative wound complications, reoperation and re-admission with the use of more aggressive anticoagulation regimens, such as warfarin and factor Xa inhibitors. This highlights the importance of the safety, as well as efficacy, of the chemoprophylactic regimen. Results Studies have shown a symptomatic VTE rate of 0.92% with use of MCDs for prophylaxis, which is comparable with rates seen with more aggressive anticoagulation protocols. A prior prospective study found that use of a pre-operative risk stratification protocol based on personal history of deep vein thrombosis, family history of VTE, active cancer, or a hypercoaguable state allowed for the avoidance of aggressive prophylactic anticoagulation in over 70% of patients while maintaining a low incidence of symptomatic VTE. Conclusion Further investigation is needed into the role of aspirin in VTE prophylaxis as well as the efficacy of MCDs as stand-alone prophylactic treatment.
UR - http://www.scopus.com/inward/record.url?scp=85021194607&partnerID=8YFLogxK
U2 - 10.1302/0301-620X.99B1.BJJ-2016-0165.R1
DO - 10.1302/0301-620X.99B1.BJJ-2016-0165.R1
M3 - Article
C2 - 28042112
AN - SCOPUS:85021194607
SN - 2049-4394
VL - 99B
SP - 8
EP - 13
JO - The bone & joint journal
JF - The bone & joint journal
IS - 1
ER -